StrideBio is a product-driven, fully integrated gene therapy company focused on creating and developing innovative genetic medicines with life-changing or curative potential for patients with devastating conditions, including monogenic rare disease and beyond.
We leverage our proprietary structure-inspired adeno-associated virus (AAV) vector engineering platform to create unique and differentiated vectors that improve upon naturally occurring AAV serotypes to overcome current limitations of first-generation gene therapies. Improved characteristics of StrideBio’s AAV vectors include evasion of pre-existing neutralizing antibodies, tissue targeting and de-targeting, enhanced potency, and manufacturability at scale. Combined with our gene construct design expertise and in-house manufacturing capabilities, StrideBio is positioned to generate best-in-class genetic medicines that allow more patients to benefit with maximum efficiency.
StrideBio is based in a state-of-the-art 24,000-square-foot facility in Research Triangle Park, N.C, which houses our offices, research labs and in-house AAV manufacturing facilities.
Location: United States, North Carolina, Durham
Employees: 51-200
Total raised: $97.2M
Founded date: 2015
Investors 4
| Date | Name | Website |
| - | Takeda Ven... | takeda.com |
| - | UCB Ventur... | ucbventure... |
| - | Octagon Ca... | octagoninv... |
| - | Pontifax V... | pontifax.c... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 16.03.2021 | Series B | $81.5M | - |
| 14.06.2018 | Series A | $15.7M | - |
Mentions in press and media 19
| Date | Title | Description | Source |
| 16.03.2021 | StrideBio Announces Closing of $81.5M Series B Financing | RESEARCH TRIANGLE PARK, N.C., March 16, 2021 /PRNewswire/ -- StrideBio, Inc., a leading developer ... | prnewswire... |
| 16.03.2021 | StrideBio Closes $81.5M Series B Financing | StrideBio, Inc., a Research Triangle Park, N.C.-based developer of novel engineered adeno-associated... | finsmes.co... |
| 16.03.2021 | StrideBio Announces Closing of $81.5M Series B Financing | RESEARCH TRIANGLE PARK, N.C., March 16, 2021 /PRNewswire/ -- StrideBio, Inc., a leading developer of... | marketscre... |
| 16.03.2021 | StrideBio Announces Closing of $81.5M Series B Financing | Research Triangle Park, N.C., Mar. 16, 2021 – StrideBio, Inc., a leading developer of novel engineer... | ucbventure... |
| 16.03.2021 | StrideBio Raises $81.5M Series B Round | RESEARCH TRIANGLE PARK, NC, StrideBio today announced the closing of an oversubscribed Series B fu... | vcnewsdail... |
| 03.01.2019 | Hatteras Venture Partners-backed StrideBio Appoints Sapan Sh... | StrideBio, Inc, a leading developer of novel adeno-associated viral (AAV) based gene therapies, anno... | archive.ci... |
| 03.01.2019 | Hatteras Venture Partners-backed StrideBio Appoints Sapan Sh... | StrideBio, Inc, a leading developer of novel adeno-associated viral (AAV) based gene therapies, anno... | citybizlis... |
| 14.06.2018 | Term Sheet — Thursday, June 14 | 5 Qs WITH A DEALMAKER You probably haven’t heard of Fleetcor Technologies. Paid Content How can yo... | fortune.co... |
| 14.06.2018 | StrideBio Raises $15.7M Series A | StrideBio, Inc, a US-based company developing novel AAV vectors for in vivo gene therapies announced... | citybizlis... |
| 13.06.2018 | StrideBio Closes $15.7M in Series A Financing | StrideBio, Inc., a Durham, NC-based company developing novel AAV vectors for in vivo gene therapies,... | finsmes.co... |
Show more